<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03728725</url>
  </required_header>
  <id_info>
    <org_study_id>7162-02/2</org_study_id>
    <nct_id>NCT03728725</nct_id>
  </id_info>
  <brief_title>Xpert MTB/XDR Clinical Evaluation Trial</brief_title>
  <official_title>Multicentre Clinical Trial to Assess the Performance of the Xpert MTB/XDR Assay for INH- and Second-line Resistance Detection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foundation for Innovative New Diagnostics, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cepheid</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>PD Hinduja Hospital and Medical Research Centre, Mumbai, India</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Phthisiopneumology Institute, Chisinau, Moldova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Tuberculosis and Respiratory Disease, New Delhi, India</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Witwatersrand, South Africa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Foundation for Innovative New Diagnostics, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      FIND and partners intend to address the need for a multi- and extensively drug-resistant&#xD;
      tuberculosis (M/XDR-TB) diagnostic solution for patients in settings with a high burden of&#xD;
      drug-resistant tuberculosis (DR-TB) though the development, evaluation and introduction of an&#xD;
      Xpert MTB/XDR assay&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 11, 2019</start_date>
  <completion_date type="Actual">August 18, 2020</completion_date>
  <primary_completion_date type="Actual">August 18, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Estimate the diagnostic accuracy of the Xpert MTB/XDR assay for INH and ETH resistance detection</measure>
    <time_frame>Day 1</time_frame>
    <description>Sensitivity and specificity estimates for INH and ETH resistance detection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimate the diagnostic accuracy of the Xpert MTB/XDR assay for fluoroquinolone resistance detection</measure>
    <time_frame>Day 1</time_frame>
    <description>Sensitivity and specificity estimates for fluoroquinolone resistance detection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimate the diagnostic accuracy of the Xpert MTB/XDR assay for second-line injectable resistance detection</measure>
    <time_frame>Day 1</time_frame>
    <description>Sensitivity and specificity estimates for second-line injectable resistance detection</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">710</enrollment>
  <condition>Tuberculosis, Pulmonary</condition>
  <condition>Tuberculosis, Multidrug-Resistant</condition>
  <arm_group>
    <arm_group_label>TB case detection Group</arm_group_label>
    <description>Patients with pulmonary TB symptoms and at least one DR-TB risk factor will be screened by Xpert MTB/RIF or Ultra. Patients with a clear TB-positive and RIF-resistant or RIF-sensitive result by Xpert MTB/RIF or Ultra and who consent to study procedures will be tested by Xpert MTB/XDR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RIF-resistance MTB Group</arm_group_label>
    <description>An anticipated 316 additional RIF-resistant patients, as detected by Xpert MTB.&#xD;
/RIF, will be enrolled in this study to evaluate sensitivity and specificity of the Xpert MTB/XDR test against strains with other potential drug-resistance mutations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cepheid Gene Xpert MTB/XDR</intervention_name>
    <description>The Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA) is an integrated, automated, cartridge-based system for MDR-TB diagnosis that uses the GeneXpert instrument platform. WHO confirmed evidence to support the widespread use of the Xpert MTB/RIF assay in 2010 and the assay has since been widely used in TB programs, but it is only capable of identifying Mycobacterium tuberculosis (Mtb) and detecting RIF resistance. The Xpert MTB/XDR assay will be evaluated for INH and second-line resistance detection, and to recommend its use in diverse clinical settings. The focus of this protocol is the multicentre clinical evaluation.</description>
    <arm_group_label>RIF-resistance MTB Group</arm_group_label>
    <arm_group_label>TB case detection Group</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Sputum will be collected from consenting, enrolled adult participants. Sputum samples may&#xD;
      voluntarily be stored for up to 20 years.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals who have one or more risk factors for DR-TB presenting to participating centres&#xD;
        will be screened by Xpert MTB/RIF or Ultra. Those who test MTB-positive by Xpert MTB/RIF or&#xD;
        Ultra at the study sites will be asked to participate. Individuals will be recruited at&#xD;
        outpatient clinic settings and inpatient hospital settings. HIV-positive individuals and&#xD;
        HIV-negative individuals will be included in this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Age 18 years or above;&#xD;
&#xD;
               -  Symptoms suggesting pulmonary TB, i.e. persistent cough (generally ≥3 weeks or as&#xD;
                  per local definition of TB suspect), and at least one of the following:&#xD;
&#xD;
                    -  Previously received &gt;1 month of treatment for a prior TB episode or&#xD;
&#xD;
                    -  Failing TB treatment with positive sputum smear or culture after ≥3 months&#xD;
                       of a standard TB treatment or&#xD;
&#xD;
                    -  Had close contact with a known drug-resistant TB case or&#xD;
&#xD;
                    -  Newly diagnosed with MDR-TB within the last 30 days or&#xD;
&#xD;
                    -  Previously diagnosed with MDR-TB and failed TB treatment with positive&#xD;
                       sputum smear or culture after ≥3 months of a standard MDR-TB treatment&#xD;
                       regimen&#xD;
&#xD;
        Patients meeting the above criteria will be screened by Xpert MTB/RIF or Xpert MTB/RIF&#xD;
        Ultra. TB patients meeting the following criteria will be included in the study:&#xD;
&#xD;
          -  A clear Mtb-positive and RIF-resistant or RIF-sensitive result by Xpert MTB/RIF or&#xD;
             Xpert MTB/RIF Ultra&#xD;
&#xD;
          -  Provision of informed consent;&#xD;
&#xD;
          -  Production of an adequate quantity (&gt;3mL) of sputum&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants will be excluded from the study if informed consent is not provided.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institute of Pthisiopenumology</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Moldova, Republic of</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 5, 2018</study_first_submitted>
  <study_first_submitted_qc>November 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2018</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
    <mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data sharing statement Individual, de-identified participant data will be shared, including data dictionaries. Other documents that have been made available include the study protocol and statistical analysis plan. Templates of the informed consent forms may be shared upon request. The data will be available immediately following publication with no end date. The data will be shared with anyone who wishes to access the data. The data will be available for any purpose of analyses. For data, please contact the corresponding author.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Upon publication of final study results</ipd_time_frame>
    <ipd_access_criteria>The data will be shared with anyone who wishes to access the data.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT03728725/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 7, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT03728725/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

